Contact
Bone Therapeutics

Management

Thomas Lienard  MBA – Chief Executive Officer

Thomas Lienard

Thomas Lienard has over 15 years of national and international sales and marketing experience in the pharmaceutical industry.

Prior to joining Bone Therapeutics, Thomas Lienard worked at Lundbeck, where he acted as Managing Director for Belgium and Luxemburg and was vital to the launch of several products. He led a team of up to 80 employees, generating over EUR 50 million in sales. Before his position at Lundbeck, he worked at Eli Lilly and Company, where he held various positions in sales and marketing in Europe and the US, including Sales Director Belgium in 2010. Thomas Lienard started his career in 1999 as consultant a McKinsey & Company. He graduated from Solvay Brussels School of Economics and Management as Master in Business Engineering in 1999 and obtained a Master of Business Administration (MBA) from Harvard Business School in Boston in 2004.

Thomas Lienard joined Bone Therapeutics in 2015 as Chief Business Officer in charge of activities regarding business development and strategic planning and was appointed CEO in October 2016.

Jean-Luc Vandebroek   Chief Financial Officer

Wim Goemaere

Jean-Luc Vandebroek is a seasoned finance executive with extensive international finance experience at major public and privately-owned companies.

Jean-Luc has built a successful career spanning 15 years at the Belgian-US retailer, Delhaize Group (now Ahold Delhaize). During this period, he held various senior financial positions with increasing responsibility, including roles as Corporate Director Finance Europe and US and Vice President Finance BeLux. He later became Group Chief Financial Officer at Fluxys, a listed, pan-European gas infrastructure group, where he was responsible for the financing of large infrastructure investments using diverse forms of funding on capital markets.

Prior to joining Bone Therapeutics, Jean-Luc served as Director and Chief Financial Officer of Moteo Two Wheels and Bihr Europe, the motorcycle division of Alcopa Group, a Belgian family holding with an annual revenue of around EUR 1.7 billion.

Miguel Forte  MD, PhD – Chief Medical Officer

Prof. Valérie Gangji

Miguel Forte has significant regenerative medicine and cell therapy industry experience, most recently as Chief Operating and Medical Officer at TxCell, a French biotechnology company specializing in immune cell therapy, and as Chief Commercialization Officer and Chair of the Commercialization Committee at the International Society of Cellular Therapy (ISCT). With over 20 years’ industry experience, he has gained broad expertise in medical and regulatory affairs, ranging from leading early and late stage clinical trials to market authorization and the launch of new biologic products for various indications.

Prior to TxCell, Miguel Forte held several leadership positions in large pharmaceutical companies, including as Vice President, Global Medical Affairs at UCB, and various senior positions at the European Medicines Agency, Bristol-Myers Squibb, Abbott, and Wellcome Laboratories (now part of GSK).

Miguel Forte graduated in Medicine from the University of Lisbon, specializing in infectious diseases and obtained a PhD in Immunology at the University of Birmingham. He is currently Associate Professor in Health Sciences and Pharmacy at the University of Aveiro and the University of Lisbon.

Guy Heynen  MD – Chief Clinical and Regulatory Officer

Prof. Guy Heynen

Guy Heynen started his career at the Belgian National Foundation for Scientific Research and in research roles at University Hospital, Liège, Belgium where he received his degree in medicine. He is a specialist in rheumatology and immunology, with extensive experience in both university medical practice and in the pharmaceutical industry.

Guy Heynen has over 35 years' experience in medical affairs and regulatory functions at national and international levels and has a particular focus on management, team building and leadership. The majority of his career has been with Pfizer Inc. where he held a number of senior roles including medical director for Pfizer Switzerland, European team leader for the Alzheimer's disease drug Aricept and medical team leader for Pfizer's anti-inflammatory drug franchise based in New York, US.Guy Heynen also served as medical affairs director at Anbics AG, Switzerland from 2003-2006 and remains a regional medical monitor for Pfizer GmbH Berlin.

Benoît Champluvier  PhD – Chief Technology and Manufacturing Officer

Benoit Champluvier

Benoît Champluvier joins from GlaxoSmithKline Vaccines, where he has more than 20 years’ experience of driving innovation and complex bioprocesses, supporting the development and launch of a number of new products.He graduated from the Université Catholique de Louvain (UCL) in 1984 with an engineering degree in agronomics and a degree in economics. He then started a PhD in agronomic sciences at the UCL and was a postdoctoral researcher at the Institut für Enzymtechnologie in Jülich, Germany. He started his career at Jungbunzlauer in 1992. Benoît Champluvier joined GSK in 1993 as junior scientist and subsequently held a number of senior roles, such as Director Downstream Process Technology, Coordinator New Technologies & GMP Pilot Plant.

 

Nora Meskini   Director of Clinical Operations

Nora Meskini

Nora Meskini has over 19 years of experience in the execution and coordination of clinical trials. Prior to her position at Bone Therapeutics, she was Associate Director of the European Clinical Program at Cytori Therapeutics for three years. Earlier, she held positions as Program Director Clinical Operations EMEA and Senior Clinical Research Manager EMEA at Biosense Webster (Johnson & Johnson).